Treatment of superficial basal cell carcinoma with ingenol mebutate gel, 0.05%
Miriam S Bettencourt1,2 1Advanced Dermatology and Cosmetic Surgery, Henderson, 2Department of Dermatology, University of Nevada, Las Vegas, NV, USA Background: Basal cell carcinoma (BCC) is the most common cancer in Caucasians. Surgical approaches are the most widely used...
Main Author: | Bettencourt MS |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-08-01
|
Series: | Clinical, Cosmetic and Investigational Dermatology |
Subjects: | |
Online Access: | https://www.dovepress.com/treatment-of-superficial-basal-cell-carcinoma-with-ingenol-mebutate-ge-peer-reviewed-article-CCID |
Similar Items
-
Tattoo removal with ingenol mebutate
by: Cozzi SJ, et al.
Published: (2017-05-01) -
Ingenol mebutate: A novel topical drug for actinic keratosis
by: Suruchi Aditya, et al.
Published: (2013-01-01) -
Ingenol mebutate treatment in actinic keratosis – clinical effectiveness and potential side effects
by: Aleksandra Lesiak, et al.
Published: (2019-08-01) -
Relationship between severity of the local skin reactions and the rate of local skin reaction resolution in patients treated with ingenol mebutate gel
by: Jim On SC, et al.
Published: (2016-08-01) -
Ingenol mebutate in low amounts for the treatment of actinic keratosis in Korean patients
by: Joe HJ, et al.
Published: (2017-03-01)